Gouty Arthritis (Gout) - Pipeline Review, H2 2017

  • ID: 4429824
  • Report
  • 95 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • C&C Research Laboratories
  • CymaBay Therapeutics Inc
  • Genentech Inc
  • Monosol Rx LLC
  • Opsona Therapeutics Ltd
  • Rigel Pharmaceuticals Inc
  • MORE
Gouty Arthritis (Gout) - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Gouty Arthritis (Gout) - Pipeline Review, H2 2017, provides an overview of the Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline landscape.

Gout is a type of arthritis where swelling and severe pain develops in joints, especially at the base of the big toe. Gout occurs when uric acid builds up in blood and causes inflammation in the joints. Symptoms include sudden onset of joint pain, joint swelling, heat in the affected area and joint redness. Risk factors include obesity, high alcohol intake, injury to a joint, long-standing kidney disease and high intake of foods rich in purines.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Gouty Arthritis (Gout) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Gouty Arthritis (Gout) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gouty Arthritis (Gout) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 11, 1, 17, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gouty Arthritis (Gout) (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Gouty Arthritis (Gout) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gouty Arthritis (Gout) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gouty Arthritis (Gout) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gouty Arthritis (Gout) (Musculoskeletal Disorders)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gouty Arthritis (Gout) (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • C&C Research Laboratories
  • CymaBay Therapeutics Inc
  • Genentech Inc
  • Monosol Rx LLC
  • Opsona Therapeutics Ltd
  • Rigel Pharmaceuticals Inc
  • MORE
Introduction

Gouty Arthritis (Gout) - Overview

Gouty Arthritis (Gout) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Gouty Arthritis (Gout) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gouty Arthritis (Gout) - Companies Involved in Therapeutics Development

C&C Research Laboratories

CymaBay Therapeutics Inc

Genentech Inc

Immune Response BioPharma Inc

Jiangsu Hengrui Medicine Co Ltd

Monosol Rx LLC

Opsona Therapeutics Ltd

Polaris Pharmaceuticals Inc

Rigel Pharmaceuticals Inc

Swedish Orphan Biovitrum AB

Teijin Pharma Ltd

The Female Health Company

Wellstat Therapeutics Corp

XL-protein GmbH

Gouty Arthritis (Gout) - Drug Profiles

anakinra - Drug Profile

APP-112 - Drug Profile

AQB-565 - Drug Profile

arhalofenate - Drug Profile

CLX-114 - Drug Profile

colchicine - Drug Profile

D-0120 - Drug Profile

dapansutrile - Drug Profile

diacerein - Drug Profile

diacerein CR - Drug Profile

febuxostat - Drug Profile

FYU-981 - Drug Profile

HSA-Uricase - Drug Profile

IR-888 - Drug Profile

Monoclonal Antibody to Inhibit S100A9 Protein for Autoimmune Disorders, Chronic Inflammation, Neurodegenerative Diseases and Respiratory Infections - Drug Profile

ND-2110 - Drug Profile

ND-2158 - Drug Profile

ND-346 - Drug Profile

pegadricase - Drug Profile

Recombinant Enzyme for Gout and Tumor Lysis Syndrome - Drug Profile

REV-002 - Drug Profile

RLBN-1001 - Drug Profile

SHR-4640 - Drug Profile

Small Molecule to Inhibit IRAK1/4 for Arthritis and Psoriasis - Drug Profile

Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia - Drug Profile

Small Molecules for Gout - Drug Profile

Small Molecules to Inhibit GLUT9 for Gout - Drug Profile

Small Molecules to Inhibit Interleukin 1 Beta for Muckle-Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease and Gouty Arthritis - Drug Profile

Small Molecules to Inhibit NLRP3 for Gastrointestinal and Musculoskeletal Disorders - Drug Profile

TMX-049 - Drug Profile

URC-102 - Drug Profile

uriSHELS - Drug Profile

VCB-201 - Drug Profile

WT-2107 - Drug Profile

XEN-104 - Drug Profile

XL-400 - Drug Profile

Gouty Arthritis (Gout) - Dormant Projects

Gouty Arthritis (Gout) - Discontinued Products

Gouty Arthritis (Gout) - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Gouty Arthritis (Gout), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Gouty Arthritis (Gout) - Pipeline by C&C Research Laboratories, H2 2017

Gouty Arthritis (Gout) - Pipeline by CymaBay Therapeutics Inc, H2 2017

Gouty Arthritis (Gout) - Pipeline by Genentech Inc, H2 2017

Gouty Arthritis (Gout) - Pipeline by Immune Response BioPharma Inc, H2 2017

Gouty Arthritis (Gout) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017

Gouty Arthritis (Gout) - Pipeline by Monosol Rx LLC, H2 2017

Gouty Arthritis (Gout) - Pipeline by Opsona Therapeutics Ltd, H2 2017

Gouty Arthritis (Gout) - Pipeline by Polaris Pharmaceuticals Inc, H2 2017

Gouty Arthritis (Gout) - Pipeline by Rigel Pharmaceuticals Inc, H2 2017

Gouty Arthritis (Gout) - Pipeline by Swedish Orphan Biovitrum AB, H2 2017

Gouty Arthritis (Gout) - Pipeline by Teijin Pharma Ltd, H2 2017

Gouty Arthritis (Gout) - Pipeline by The Female Health Company, H2 2017

Gouty Arthritis (Gout) - Pipeline by Wellstat Therapeutics Corp, H2 2017

Gouty Arthritis (Gout) - Pipeline by XL-protein GmbH, H2 2017

Gouty Arthritis (Gout) - Dormant Projects, H2 2017

Gouty Arthritis (Gout) - Dormant Projects, H2 2017 (Contd..1), H2 2017

Gouty Arthritis (Gout) - Discontinued Products, H2 2017

List of Figures

Number of Products under Development for Gouty Arthritis (Gout), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • C&C Research Laboratories
  • CymaBay Therapeutics Inc
  • Genentech Inc
  • Immune Response BioPharma Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Monosol Rx LLC
  • Opsona Therapeutics Ltd
  • Polaris Pharmaceuticals Inc
  • Rigel Pharmaceuticals Inc
  • Swedish Orphan Biovitrum AB
  • Teijin Pharma Ltd
  • The Female Health Company
  • Wellstat Therapeutics Corp
  • XL-protein GmbH
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll